Related references
Note: Only part of the references are listed.Colistin-sparing regimens against Klebsiella pneumoniae carbapenemase-producing K-pneumoniae isolates: Combination of tigecycline or doxycycline and gentamicin or amikacin
Hung-Jen Tang et al.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2019)
Critical Review of Double-Carbapenem Therapy for the Treatment of Carbapenemase-Producing Klebsiella pneumoniae
Ola Mashni et al.
ANNALS OF PHARMACOTHERAPY (2019)
Risk factors and outcomes for the acquisition of carbapenem-resistant Gram-negative bacillus bacteremia: A retrospective propensity-matched case control study
Shih-Wen Ting et al.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2018)
In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Isolates Collected from US Hospitals and Comparative Activities of Aminoglycosides against Carbapenem-Resistant Enterobacteriaceae and Isolates Carrying Carbapenemase Genes
Mariana Castanheira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
In Vitro Activity of Imipenem-Relebactam against Clinical Isolates of Gram-Negative Bacilli Isolated in Hospital Laboratories in the United States as Part of the SMART 2016 Program
James A. Karlowsky et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects
Yutaka Saisho et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae
Jesus Rodriguez-Bano et al.
CLINICAL MICROBIOLOGY REVIEWS (2018)
Pharmacokinetic drug evaluation of avibactam plus ceftazidime for the treatment of hospital-acquired pneumonia
Marco Falcone et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2018)
Management of infections caused by extended-spectrum -lactamase-producing Enterobacteriaceae: current evidence and future prospects
Chau-Chyun Sheu et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2018)
Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection
Maddalena Giannella et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme
Michael A. Pfaller et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
Enhanced efficacy of imipenem-colistin combination therapy against multiple-drug-resistant Enterobacter cloacae: in vitro activity and a Galleria mellonella model
Haifei Yang et al.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2018)
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial
Mical Paul et al.
LANCET INFECTIOUS DISEASES (2018)
High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections A retrospective cohort study
Ting-Ting Geng et al.
MEDICINE (2018)
Association Between Carbapenem Resistance and Mortality Among Adult, Hospitalized Patients With Serious Infections Due to Enterobacteriaceae: Results of a Systematic Literature Review and Meta-analysis
Amber Martin et al.
OPEN FORUM INFECTIOUS DISEASES (2018)
Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections
Sohita Dhillon
DRUGS (2018)
Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes an other resistance mechanisms
Mariana Castanheira et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Phenotypic Detection of Carbapenemase-Producing Organisms from Clinical Isolates
Pranita D. Tamma et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2018)
Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae
Lindsay A. Petty et al.
INFECTION AND DRUG RESISTANCE (2018)
Intravenous Colistin Monotherapy versus Combination Therapy against Carbapenem-Resistant Gram-Negative Bacteria Infections: Meta-Analysis of Randomized Controlled Trials
I-Ling Cheng et al.
JOURNAL OF CLINICAL MEDICINE (2018)
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae
David van Duin et al.
CLINICAL INFECTIOUS DISEASES (2018)
Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial
Richard G. Wunderink et al.
INFECTIOUS DISEASES AND THERAPY (2018)
In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016
Meredith A. Hackel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-beta-Lactamase Inhibitor Combinations
George G. Zhanel et al.
DRUGS (2018)
Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms
Elizabeth Temkin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne blaKPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections
Ryan K. Shields et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis
Oren Zusman et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: Should we get to the PK/PD root of the paradox?
Valerio Del Bono et al.
VIRULENCE (2017)
Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae
Joshua T. Thaden et al.
VIRULENCE (2017)
Carbapenemase-producing Klebsiella pneumoniae bloodstream infection in critically ill patients: risk factors and predictors of mortality
M. Papadimitriou-Olivgeris et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2017)
Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae
M. Souli et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2017)
Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility
Alexandre P. Zavascki et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2017)
Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation
Fiorella Krapp et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2017)
Recently approved antibacterials for methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive pathogens: the shock of the new
Michael Z. David et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2017)
Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients
Juan J. Caston et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2017)
Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections
Matthew Sims et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae : the activity of the double-carbapenem regimen is related to meropenem MIC value
A. Oliva et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Double-carbapenem regimen, alone or in combination with colistin, in the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae (CR-Kp)
Alessandra Oliva et al.
JOURNAL OF INFECTION (2017)
The plasmid-mediated fosfomycin resistance determinants and synergy of fosfomycin and meropenem in carbapenem-resistant Klebsiella pneumoniae isolates in Taiwan
Sung-Pin Tseng et al.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2017)
Presence of multidrug-resistant organisms in the residents and environments of long-term care facilities in Taiwan
Chun-Ming Lee et al.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2017)
Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance
Yee-Huang Ku et al.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2017)
Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study
Belen Gutierrez-Gutierrez et al.
LANCET INFECTIOUS DISEASES (2017)
Drug-resistant bacteria ranked
Cassandra Willyard
NATURE (2017)
Therapeutic options for carbapenem-resistant Enterobacteriaceae infections
Enrico Maria Trecarichi et al.
VIRULENCE (2017)
Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial A Randomized Clinical Trial
Joseph Solomkin et al.
JAMA SURGERY (2017)
Double carbapenem therapy (DCT) for bacteremia due to carbapenem-resistant Klebsiella pneumoniae (CRKP): from test tube to clinical practice
Veena Venugopalan et al.
INFECTIOUS DISEASES (2017)
Improved Outcomes with Plazomicin (PLZ) Compared with Colistin (CST) in Patients with Bloodstream Infections (BSI) Caused by Carbapenem-resistant Enterobacteriaceae (CRE): Results from the CARE Study
James A McKinnell et al.
Open Forum Infectious Diseases (2017)
New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn?
H. Wright et al.
CLINICAL MICROBIOLOGY AND INFECTION (2017)
Resistance to Ceftazidime-Avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux Activity
Kirk Nelson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae
Mariana Castanheira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Synergistic activities of meropenem double and triple combinations against carbapenemase-producing Enterobacteriaceae
Marlene Fredborg et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2017)
Synergistic activity of ceftazidime-avibactam and aztreonam against serine and metallo-β-lactamase-producing gram-negative pathogens
Eric Wenzler et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2017)
Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia
Ryan K. Shields et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems
Isabel Machuca et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections: a two-center, matched case-control study
Gennaro De Pascale et al.
CRITICAL CARE (2017)
Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections
Madeline King et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Novel Beta-Lactamase Inhibitors: Unlocking Their Potential in Therapy
Darren Wong et al.
DRUGS (2017)
Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
Steven Marshall et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Influence of Colistin Dose on Global Cure in Patients with Bacteremia Due to Carbapenem-Resistant Gram-Negative Bacilli
Gabrielle A. Gibson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations
Herve Dupont et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Infection control implications of heterogeneous resistance mechanisms in carbapenem-resistant Enterobacteriaceae (CRE)
K. E. Goodman et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2016)
In vitro evaluation of dual carbapenem combinations against carbapenemase-producing Enterobacteriaceae
Laurent Poirel et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey
Enrico Maria Trecarichi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection
Christopher Lucasti et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa
Akinobu Ito et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
In Vitro Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii
David M. Livermore et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae
Mariana Castanheira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014)
Boudewijn L. M. de Jonge et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections
Ryan K. Shields et al.
CLINICAL INFECTIOUS DISEASES (2016)
Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent
George G. Zhanel et al.
DRUGS (2016)
New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance
Ling-Shan Syue et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2016)
Carbapenemase-producing Klebsiella pneumoniae bloodstream infections in neutropenic patients with haematological malignancies or aplastic anaemia: Analysis of 50 cases
Polydoros Tofas et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2016)
In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline
Yunliang Zhang et al.
JOURNAL OF ANTIBIOTICS (2016)
Tigecycline Treatment for Carbapenem-Resistant Enterobacteriaceae Infections A Systematic Review and Meta-Analysis
Wentao Ni et al.
MEDICINE (2016)
Ceftazidime-Avibactam Activity Tested against Enterobacteriaceae Isolates from US Hospitals (2011 to 2013) and Characterization of β-Lactamase-Producing Strains
Mariana Castanheira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Efficacy of polymyxins in the treatment of carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis
Wentao Ni et al.
BRAZILIAN JOURNAL OF INFECTIOUS DISEASES (2015)
Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case-control-control study
D. R. Giacobbe et al.
CLINICAL MICROBIOLOGY AND INFECTION (2015)
Plazomicin: an investigational therapy for the treatment of urinary tract infections
Ilias Karaiskos et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2015)
Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study
Mario Tumbarello et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
The -Lactams Strike Back: Ceftazidime-Avibactam
Evan J. Zasowski et al.
PHARMACOTHERAPY (2015)
Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management
Keith S. Kaye et al.
PHARMACOTHERAPY (2015)
Antibiotic Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae: Systematic Evaluation of the Available Evidence
Matthew E. Falagas et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
In Vitro Activity of Plazomicin against 5,015 Gram-Negative and Gram- Positive Clinical Isolates Obtained from Patients in Canadian Hospitals as Part of the CANWARD Study, 2011-2012
A. Walkty et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Carbapenemase-Producing Klebsiella pneumoniae Bloodstream Infections: Lowering Mortality by Antibiotic Combination Schemes and the Role of Carbapenems
George L. Daikos et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®
Timothy A. Blizzard et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
Successful control of a hospital-wide outbreak of OXA-48 producing Enterobacteriaceae in the Netherlands, 2009 to 2011
M J Dautzenberg et al.
Eurosurveillance (2014)
Tigecycline therapy for infections due to carbapenemase-producing Klebsiella pneumoniae in critically ill patients
B. Balandin Moreno et al.
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES (2014)
High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria
Gennaro De Pascale et al.
CRITICAL CARE (2014)
Human Simulated Studies of Aztreonam and Aztreonam-Avibactam To Evaluate Activity against Challenging Gram-Negative Organisms, Including Metallo-β-Lactamase Producers
Jared L. Crandon et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Antibacterial Activity of Eravacycline (TP-434), a Novel Fluorocycline, against Hospital and Community Pathogens
J. A. Sutcliffe et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Carbapenem-Sparing Antibiotic Regimens for Infections Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Intensive Care Unit
Francesco Sbrana et al.
CLINICAL INFECTIOUS DISEASES (2013)
High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality
A. Capone et al.
CLINICAL MICROBIOLOGY AND INFECTION (2013)
Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae: a major clinical challenge
C. Navarro-San Francisco et al.
CLINICAL MICROBIOLOGY AND INFECTION (2013)
Impact of various conditions on the efficacy of dual carbapenem therapy against KPC-producing Klebsiella pneumoniae
Dora E. Wiskirchen et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2013)
Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases
L. Silvia Munoz-Price et al.
LANCET INFECTIOUS DISEASES (2013)
KPC-3 Klebsiella pneumoniae ST258 clone infection in postoperative abdominal surgery patients in an intensive care setting: analysis of a case series of 30 patients
Paola Di Carlo et al.
BMC ANESTHESIOLOGY (2013)
Novel β-lactamase inhibitors: a therapeutic hope against the scourge of multidrug resistance
Richard R. Watkins et al.
FRONTIERS IN MICROBIOLOGY (2013)
Treatment Outcome of Bacteremia Due to KPC-Producing Klebsiella pneumoniae: Superiority of Combination Antimicrobial Regimens
Zubair A. Qureshi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Predictors of Mortality in Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Importance of Combination Therapy
Mario Tumbarello et al.
CLINICAL INFECTIOUS DISEASES (2012)
Carbapenemases in Klebsiella pneumoniae and Other Enterobacteriaceae: an Evolving Crisis of Global Dimensions
L. S. Tzouvelekis et al.
CLINICAL MICROBIOLOGY REVIEWS (2012)
Double-Carbapenem Therapy for Carbapenemase-Producing Klebsiella pneumoniae
Catharine C. Bulik et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?
G. L. Daikos et al.
CLINICAL MICROBIOLOGY AND INFECTION (2011)
Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes
Matthew E. Falagas et al.
FUTURE MICROBIOLOGY (2011)
What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline
David M. Livermore et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2011)
Efficacy of carbapenems against a metallo-β-lactamase-producing Escherichia coli clinical isolate in a rabbit intra-abdominal abscess model
Maria Souli et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
ST11, the dominant clone of KPC-producing Klebsiella pneumoniae in China
Yan Qi et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Comparison of the Activity of a Human Simulated, High-Dose, Prolonged Infusion of Meropenem against Klebsiella pneumoniae Producing the KPC Carbapenemase versus That against Pseudomonas aeruginosa in an In Vitro Pharmacodynamic Model
Catharine C. Bulik et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
In Vivo Efficacy of Simulated Human Dosing Regimens of Prolonged-Infusion Doripenem against Carbapenemase-Producing Klebsiella pneumoniae
Catharine C. Bulik et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City
David Landman et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study
Karthikeyan K. Kumarasamy et al.
LANCET INFECTIOUS DISEASES (2010)
How antibiotics kill bacteria: from targets to networks
Michael A. Kohanski et al.
NATURE REVIEWS MICROBIOLOGY (2010)
Prospective Observational Study of the Impact of VIM-1 Metallo-β-Lactamase on the Outcome of Patients with Klebsiella pneumoniae Bloodstream Infections
George L. Daikos et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
ACHN-490, a Neoglycoside with Potent In Vitro Activity against Multidrug-Resistant Klebsiella pneumoniae Isolates
Andrea Endimiani et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA
Andrea Endimiani et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
Ongoing epidemic of bla(VIM-1)-positive Klebsiella pneumoniae in Athens, Greece: a prospective survey
M. Psichogiou et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobactetiaceae
K. F. Anderson et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2007)
Activity of imipenem against VIM-1 metallo-β-lactamase-producing Klebsiella pneumoniae in the murine thigh infection model
G. L. Daikos et al.
CLINICAL MICROBIOLOGY AND INFECTION (2007)
Outbreak of infection with multidrug-resistant Klebsiella pneumoniae carrying blaIMP-8 in a university medical center in Taiwan
JJ Yan et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2001)
Share Paper
